Patient and donor characteristics
| No. of patients | 84 |
| Follow-up in months, mean (range) | 24 (1-70) |
| Patient's median age (range) | 42 (21-59) |
| Diagnosis | |
| AML/ALL | 36 (42.8%) |
| MDS | 8 (9.5%) |
| CML CP1 | 19 (22.6%) |
| NHL/CLL/MM | 20 (23.8%) |
| Histiocytosis X | 1 (1.2%) |
| Stage of disease | |
| Early | 60 (71%) |
| Advanced | 24 (29%) |
| Sex | |
| F to M | 13 (15.5%) |
| M to M | 34 (40.5%) |
| F to F | 19 (22.6%) |
| M to F | 18 (21.4%) |
| CMV serology | |
| D(−) and R(−) | 15 (17.8%) |
| D(+) and R(−) | 10 (11.9%) |
| D(−) and R(+) | 19 (22.7%) |
| D(+) and R(+) | 40 (47.6%) |
| Cell content of the graft,*median (range) | |
| CD34+cells* | 3.9 (1.2-14.3) |
| CD3+cells* | 0.3 (0.1-2) |
| Cryopreservation | 34 (40.5%) |
| Preparative regimen | |
| TBI (13 Gy) + Cy (120 mg/kg) | 75 (90%) |
| TBI (12 Gy) + Melph (110 mg/kg) | 3 (3.6%) |
| Bu (16) + Cy (120 mg/kg) | 6 (6.4%) |
| GVHD prophylaxis | |
| CsA + PDN | 54 (64%) |
| CsA | 30 (36%) |
| No. of patients | 84 |
| Follow-up in months, mean (range) | 24 (1-70) |
| Patient's median age (range) | 42 (21-59) |
| Diagnosis | |
| AML/ALL | 36 (42.8%) |
| MDS | 8 (9.5%) |
| CML CP1 | 19 (22.6%) |
| NHL/CLL/MM | 20 (23.8%) |
| Histiocytosis X | 1 (1.2%) |
| Stage of disease | |
| Early | 60 (71%) |
| Advanced | 24 (29%) |
| Sex | |
| F to M | 13 (15.5%) |
| M to M | 34 (40.5%) |
| F to F | 19 (22.6%) |
| M to F | 18 (21.4%) |
| CMV serology | |
| D(−) and R(−) | 15 (17.8%) |
| D(+) and R(−) | 10 (11.9%) |
| D(−) and R(+) | 19 (22.7%) |
| D(+) and R(+) | 40 (47.6%) |
| Cell content of the graft,*median (range) | |
| CD34+cells* | 3.9 (1.2-14.3) |
| CD3+cells* | 0.3 (0.1-2) |
| Cryopreservation | 34 (40.5%) |
| Preparative regimen | |
| TBI (13 Gy) + Cy (120 mg/kg) | 75 (90%) |
| TBI (12 Gy) + Melph (110 mg/kg) | 3 (3.6%) |
| Bu (16) + Cy (120 mg/kg) | 6 (6.4%) |
| GVHD prophylaxis | |
| CsA + PDN | 54 (64%) |
| CsA | 30 (36%) |
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodisplastic syndrome; CML, chronic myeloid leukemia; CP, chronic phase; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; F, female; M, male; CMV, cytomegalovirus; D, donor; R, recipient; TBI, total body irradiation; Cy, cytoxan; Melph, melphalan; Bu, busulphan; GVHD, graft-versus-host disease; CsA, cyclosporine A; PDN, methylprednisolone.
× 106/kg.